NDC properties for "0.5 ML Xyosted 100 MG/ML Auto-Injector" (RxCUI 2099691)
About this data
The tables show NDC propoerties for 0.5 ML Xyosted 100 MG/ML Auto-Injector with the RxCUI 2099691
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product
Details for 0.5 ML Xyosted 100 MG/ML Auto-Injector (RxCUI 2099691)
| MMSL_CODE | BD33831 |
|---|---|
| NDA | NDA209863 |
| RxCUI | 2099691 |
| SPL_SET_ID | 8a3d204c-be26-49e0-8599-0ac12a272e81 |
| Prescribable Synonym | XYOSTED 50 MG in 0.5 ML Auto-Injector |
| RXNAV_STR | 0.5 ML Xyosted 100 MG/ML Auto-Injector |
| RxNorm Name | 0.5 ML testosterone enanthate 100 MG/ML Auto-Injector [Xyosted] |
| RxNorm Synonym | 0.5 ML Xyosted 100 MG/ML Auto-Injector |
| RxNorm Synonym | Xyosted 50 MG per 0.5 ML Auto-Injector |
| Related queries | Interactions (for RxCUI 2099691) |
NDC Properties
NDC Item 54436025001
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-01 |
| NDC Item | 54436025001 |
| Packaging | 1 SYRINGE in 1 CARTON (54436-250-01) / .5 mL in 1 SYRINGE (54436-250-03) |
| DCSA | CIII |
| FDA SPL set id | 760387 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-250 |
NDC Item 54436025002
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-02 |
| NDC Item | 54436025002 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 760387 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-250 |
NDC Item 54436025003
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-03 |
| NDC Item | 54436025003 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 760387 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-250 |
NDC Item 54436025004
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-04 |
| NDC Item | 54436025004 |
| Packaging | 4 SYRINGE in 1 CARTON (54436-250-04) / .5 mL in 1 SYRINGE (54436-250-02) |
| DCSA | CIII |
| FDA SPL set id | 760387 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-250 |
NDC Item 54436025001
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-01 |
| NDC Item | 54436025001 |
| Packaging | 1 SYRINGE in 1 CARTON (54436-250-01) / .5 mL in 1 SYRINGE (54436-250-03) |
| DCSA | CIII |
| FDA SPL set id | 760387 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-250 |
NDC Item 54436025002
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-02 |
| NDC Item | 54436025002 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 760387 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-250 |
NDC Item 54436025003
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-03 |
| NDC Item | 54436025003 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 760387 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-250 |
NDC Item 54436025004
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-04 |
| NDC Item | 54436025004 |
| Packaging | 4 SYRINGE in 1 CARTON (54436-250-04) / .5 mL in 1 SYRINGE (54436-250-02) |
| DCSA | CIII |
| FDA SPL set id | 760387 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-250 |
NDC Item 54436025001
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-01 |
| NDC Item | 54436025001 |
| Packaging | 1 SYRINGE in 1 CARTON (54436-250-01) / .5 mL in 1 SYRINGE (54436-250-03) |
| DCSA | CIII |
| FDA SPL set id | 760387 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-250 |
NDC Item 54436025002
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-02 |
| NDC Item | 54436025002 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 760387 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-250 |
NDC Item 54436025003
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-03 |
| NDC Item | 54436025003 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 760387 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-250 |
NDC Item 54436025004
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-04 |
| NDC Item | 54436025004 |
| Packaging | 4 SYRINGE in 1 CARTON (54436-250-04) / .5 mL in 1 SYRINGE (54436-250-02) |
| DCSA | CIII |
| FDA SPL set id | 760387 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-250 |
NDC Item 54436025001
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-01 |
| NDC Item | 54436025001 |
| Packaging | 1 SYRINGE in 1 CARTON (54436-250-01) / .5 mL in 1 SYRINGE (54436-250-03) |
| DCSA | CIII |
| FDA SPL set id | 760387 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-250 |
NDC Item 54436025002
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-02 |
| NDC Item | 54436025002 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 760387 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-250 |
NDC Item 54436025003
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-03 |
| NDC Item | 54436025003 |
| Packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 760387 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-250 |
NDC Item 54436025004
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-04 |
| NDC Item | 54436025004 |
| Packaging | 4 SYRINGE in 1 CARTON (54436-250-04) / .5 mL in 1 SYRINGE (54436-250-02) |
| DCSA | CIII |
| FDA SPL set id | 760387 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
| Related queries | Properties for NDC 9 54436-250 |